Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET Lu-DOTATATE. The administered activity was based on 3.7 GBq/m 2 body surface area in three to five cycles, with amino acid infusion for nephroprotection. Results The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p=0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p>0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. 
Introduction
The choice of an appropriate treatment option as far as patients with inoperable or metastatic neuroendocrine tumours (NET) are concerned is limited. The response rate of chemotherapy is only at the level of 20-35% [1] , effective in a minority of patients with poorly differentiated NETs and is completely ineffective in the majority of welldifferentiated NETs. "Cold" somatostatin analogues exert a good clinical effect, decreasing flushing, diarrhoea and other symptoms of carcinoid syndrome [2, 3] .
Worth mentioning is the fact that a prospective randomized study of the effect of octreotide LAR in the control of tumour growth in patients with metastatic midgut NETs (PROMID study) showed that octreotide LAR inhibits tumour growth in patients with well-differentiated metastatic midgut NETs [4] .
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has become an established method of treatment of disseminated NET. In, the best results were observed in patients with small tumours and relatively high tumour uptake [5] . Recently, new somatostatin analogues that can be labelled with beta-emitting radionuclides have been developed. Currently Y emits beta particles with a high maximum energy (E max 2.27 MeV) and long maximum particle range in tissues (10 mm), whereas 177 Lu has lower energy (E max 0.497 MeV) and a shorter particle range in tissues (maximum 2-4 mm).
This isotope has a small γ-emission which makes it suitable for post-therapeutic scintigraphic imaging [133 keV (6. -lanreotide ( 90 Y-DOTALAN) in 154 patients has shown a partial response (PR) and disease stabilization in 14 and 41% of patients, respectively [10] .
Recent advances in somatostatin analogues have paved the way to the development of octreotate, which can be labelled with both 177 Lu and 90 Y radionuclides and is characterized by a higher affinity for somatostatin receptor type 2 leading to high tumour uptake.
The first clinical results of [ 177 Lu-DOTA 0 ,Tyr 3 ,Thr 8 ] octreotate (DOTATATE) therapy with a cumulative dose of 22.2-29.6 GBq were described in 34 patients with gastroenteropancreatic (GEP) NET. The patients were followed up 3-6 months after receiving the final dose [11] . At 3 months after the final administration, complete response (CR) was found in 1 patient (3%), PR in 12 patients (35%), stable disease (SD) in 14 patients (41%) and progressive disease (PD) in 7 patients (21%). The side effects of PRRT were few and mostly transient, with mild bone marrow suppression and nephrotoxicity, which were the most common finding.
de Jong et al. were the first to have described the use of combination treatment consisting of 50% 177 Lu-DOTATATE and 50% 90 Y-DOTATOC in rats, demonstrating that survival rates were three times longer [12, 13] . To our knowledge, there are no studies in the literature that evaluated the use of this combination treatment in human subjects. Y-DOTATATE alone, using overall survival (OS) and progression-free survival (PFS) as primary clinical end points.
Materials and methods
The study was approved by the Ethics Committee of the Medical University of Warsaw. All patients gave written informed consent.
Patients
Fifty patients with histological confirmation of metastatic NETs (WHO II) were enrolled in the study. At the time of treatment all patients showed PD confirmed by CT examination, somatostatin receptor scintigraphy (SRS) and/or increasing blood concentration of chromogranin A (CgA).
Patients were divided into two groups. Group A consisting of 25 patients (11 men and 14 women) with a mean age (± SD) of 57.3±10.6 years was treated with 90 Y-DOTATATE. Group B consisting of 25 patients (9 men and 16 women) with a mean age (± SD) of 56± 11.6 years was treated with a combination treatment including 90 Y and 177 Lu in one i.v. application. The major criterion for inclusion into this study was the benefit from PRRT therapy. Because of the fact that it was the first PRRT study in Poland, patients had extended disease. The Karnofsky index was used for estimating the patients' general condition.
The following inclusion criteria for therapy were used: [14] . For patients receiving cold long-acting somatostatin analogues, the radionuclide therapy was performed 5 weeks after the completion of octreotide (Sandostatin LAR, Novartis) and 3 weeks after lanreotide (Somatuline, Ipsen). Patients who received chemotherapy were not treated with PRRT until after a period of 3 months.
Patients were given a follow-up examination in the clinic post PRRT at 3, 6, 12, 24 and 36 months using blood tests, CT and 99m Tc-HYNIC-TATE following the same protocols as the ones used prior to therapy.
Radiopharmaceuticals
99m Tc-HYNIC-TATE: the detailed method of kit preparation and labelling with 99m Tc was presented before [14, 15] . Briefly, the peptide conjugate HYNIC-Tyr 3 -octreotate (piChem, Graz, Austria) was prepared in the dried kit form under aseptic conditions (Institute of Atomic Energy POLATOM, Poland) after adding commercially available stannous chloride, mannitol, tricine, and N,N′-ethylenediaminediacetic acid. Quality control was performed by instant thin-layer chromatography silica gel (ITLC-SG) strips (Pall) developed in 0.9% saline for the determination of non-peptide-bound radioactivity.
The labelling yield efficiency exceeded 90% in all cases. Tests for sterility and bacterial endotoxins were routinely performed.
90 Y-DOTATATE and 90 Y/ 177 Lu-DOTATATE dried kits containing 100 μg (DOTA-Tyr 3 -octreotate) (piChem, Graz, Austria) and 50.0 mg of commercially available ascorbic acid were prepared under aseptic conditions. For labelling the content of each kit vial was dissolved in not more than 0.5 ml of 90 Y no-carrier-added chloride of desired radioactivity (max. 6.5 GBq per kit) or 177 Lu carrier-added (specific activity of around 555 GBq/mg Lu) chloride solution, both isotopes provided by the Institute of Atomic Energy POLATOM, Poland. In case of low volume 0.9% NaCl was used to fill up to 0.5 ml. Incubation was carried out at 95°C for 25 min. After cooling down to room temperature, the volume was increased up to 1.5-2.0 ml with 0.9% NaCl. The preparation was sterilized by filtration with 0.22-μm filters (Millipore) to sterile glass vials followed by filter wash with 50 mg/ml ascorbic acid to the final radioactive concentration of 740 MBq/ml. The radiochemical purity (RCP) was assessed by HPLC (column: Synergy 4 Fusion RP 80A 150×4.6 mm, flow rate 0.6 ml/min, UV detection at 220 nm and radiometric detection, solvent A: 0.1% trifluoroacetic acid in water, solvent B: acetonitrile, gradient: 0 min 18% B; 9 min 60% B; 12 min 60% B; 15 min 18% B; 21 min 18% B) and Sep-Pak C18 (Waters) mini-column separation according to the supplier's instructions. 
Post-therapy imaging
A whole-body scan (256 × 256 matrix, 8-min acquisition per cm) and single photon emission computed tomography (SPECT) acquisition of the abdomen (128 × 128 matrix, 6º × 60 s) were performed using the dualhead Varicam camera (GE) with parallel-hole, highenergy, general purpose collimators [energy window centred on 177 Lu photopeak (216 keV) and a ±10% window width].
Bremsstrahlung imaging whole-body scans in 256 × 256 matrix, 8 cm/min was performed in ten patients 24 h post 90 Y-DOTATATE therapy again using the dual-head Varicam camera (GE) with a parallel-hole, low-energy, highresolution collimator (energy window centred on 100 keV with a window width of ±35%) [20] .
Evaluation of results and assessment of clinical benefit
The staging of disease and treatment response were evaluated at 3, 6, 12, 24 and 36 months follow-up. Blood tests were repeated every 7 days, others between 14 and 21 days after each cycle of therapy, and finally 3, 6, 12, 24 and 36 months after the completion of the therapy. Response to treatment on CT was defined according to Response Evaluation Criteria in Solid Tumors (RECIST). Side effects were scored according to the WHO criteria.
Event-free survival (EFS) was defined as the time from PRRT to the first evidence of progression or relapse, or to death. OS was defined as the time from PRRT to death from any cause.
The following progression criteria were defined: Means and standard deviations, medians and quartiles or frequencies depending on the parameters' distribution were used to summarize patient characteristics. The difference between comparable parameters was checked on the basis of Mann-Whitney and Wilcoxon tests.
OS, EFS and probability of 24-month survival were calculated on Kaplan-Meier estimator and compared via the log-rank test [21] . Model assumptions were tested on the basis of Schoenfeld residuals and in cases of violation the stratified model was fitted [22] .
Calculations were done in Stata v.10.1 software (Stata Statistical Software: Release 10,Stata Corporation LP, College Station, TX, USA).
Results

Patient characteristics
In the group treated with 90 Y-DOTATATE alone, 12 patients were diagnosed with foregut NETs (9 pancreas NET: 3 gastrinoma, 1 insulinoma, 5 non-functioning tumours; 3 bronchial NET), 11 patients with midgut NETs (8 carcinoid, 3 small intestinal), 1 patient with hindgut NET (rectal NET) and 1 patient with unknown primary tumours.
In the group treated with a combination of 90 Y/ 177 Lu-DOTATATE, 13 patients were diagnosed with foregut NETs Lu-DOTATATE using 177 Lu photopeak
There was no statistical difference in comparable parameters (age, sex, origin of tumours, size of metastases on CT, CgA, number and localization of metastases and treatment before PRRT). A Karnofsky performance status ≥ 80 was seen in the majority of patients; only two patients in both groups had a status ≥ 60.
Detailed patient characteristics are listed in Table 1 .
Post-therapeutic imaging
Post-therapeutic scans were performed to evaluate the biodistribution of tracer. In all cases increased uptake in the tumours and metastases was observed, compared to the liver background on qualitative analysis. The results of posttherapeutic images in all cases were comparable with the distribution of disease on 99m
Tc-HYNIC-TATE imaging ( Figs. 1 and 2) . Following post-therapeutic scans uptake in the majority of patients was unchanged. Only in two patients (one in group A and one in group B) were decreasing uptake and decrease in size of the liver metastatic lesions observed.
Results of therapy
The median follow-up observation period in group A was 37.7 months and the interquartile range (IQR) for the observation period was 20.5-46.7 months. In group B the median follow-up observation period was 34.6 months and the IQR was 25.2-39.5 months.
In Lu-DOTATATE was statistically significantly longer (p<0.027) (Fig. 3) (Fig. 4) . The probability of 24-month PFS was 44 and 57%, respectively.
At Lu-DOTATATE and progression in four patients in both groups; five and four patients died, respectively (Fig. 5b) .
At the 36-month follow-up, SD was noted in six vs eight patients and PD in one patients in both groups; four and four patients died, respectively (Fig. 5c) .
CT showed regression in size of the biggest lesions in the group treated with Lu-DOTATATE from 47 to 33 mm (Fig. 6) . The changes in both groups are not statistically significant. Correlation between tumour size before and after therapy is shown in Fig. 7 .
The patients in our study were not randomized to either group A or B but were treated first with 90 Y-DOTATATE (group A) and patients who presented later were treated with 90 Y/ 177 Lu-DOTATATE. For this reason we used the Cox analysis to evaluate the effects of the relevant prognostic factors on the survival times in each group of patients and the independence of these variables.
In the proportional hazards regression model for OS the radionuclides used, age of patients, sex, CgA level, number of lesions and size of maximal lesion were included. The model for OS was stratified by number of lesions due to a violated proportional hazards assumption.
Treatment is statistically significantly associated with OS, but not with EFS (Tables 2 and 3 Totally, for all patients at the 36-month follow-up the mean creatinine level increase was 0.07 mg/dl per year and CrCl decrease 5.1 ml/min per year.
Discussion
PRRT using radiolabelled somatostatin analogues is a promising new treatment option for patients with metastatic or inoperable somatostatin receptor-positive NETs. Clinical trials and radiochemistry examinations have demonstrated Y emits beta particles with longer path lengths and higher energies which may be preferable for larger tumours, while 177 Lu with shorter beta particle range and longer half-life may be preferable for small tumours. In our study we did not observe an influence of beta particle energy on size response of tumours (Figs. 6 and 7) . Based on the fact that 177 Lu has a longer half-life, it will take longer to deliver the same dose as 90 Y. Therefore, in patients with tumours of various sizes and non-homogeneous receptor distribution, a possible solution might be the use of a combination of radionuclides [19, 23, 24] .
Another option is a sequential administration of these analogues, e.g. Y-DOTATATE alone with a longer period of OS. In addition the labelling and administration of DOTATATE in combined therapy was straightforward, and its application was safe.
The major limitation of this analysis, like other published PRRT studies, is the lack of randomization. CT treatment response is limited to anatomical changes and it is not sensitive enough to depict functional changes. That is why, for better inclusion and evaluation of therapy response, positron emission tomography (PET)/CT techniques with 68 Ga-DOTATATE should be used, which was not available in our department during the study.
Conclusion
The results indicate that therapy with tandem radioisotopes ( 90 Y/ 177 Lu-DOTATATE) provides longer OS than with a single radioisotope ( 90 Y-DOTATATE) and the safety of both methods is comparable. It seems that OS time and EFS time rather than WHO criteria for determining tumour burden should be used to assess the response to therapy.
However, more extensive studies with a larger number of patients are required both to establish the proportion of each isotope to be used in this dual therapy and to evaluate EFS over a longer period of follow-up.
